정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2305 | Withdrawn | A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults | Coronavirus Disease | Drug: TAK-671 Drug: TAK-671 Placebo |
Phase 1 | Takeda | INDUSTRY | 0 | All | 18 Years ~ 75 Years | |
| 2304 | Terminated | A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19 | Yellow Fever | Drug: Galidesivir Drug: Placebo |
Phase 1 | BioCryst Pharmaceuticals, National Institute of Allergy and Infectious Diseases (NIAID) | INDUSTRY | 24 | All | 18 Years | Hospital de Clinicas da Universidade Federal do Parana, Curitiba, Parana, Brazil Hospital Sao Vicente de Paulo-PPDS, Passo Fundo, Rio Grande Do Sul, Brazil Hospital Sao Lucas da Pucrs, Porto Alegre, Rio Grande Do Sul, Brazil Foundation Regional Faculty of Medicine of Sao Jose do Rio Preto, Sao Jose Do Rio Preto, SP, Brazil Clinical Research Unit and Department of Infectious and Parasitic Diseases Hospital das Clinicas, School of Medicine, USP, Sao Paulo, SP, Brazil |
| 2303 | Active, not recruiting | A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults | COVID-19 | Biological: CVnCoV Vaccine Drug: Placebo |
Phase 1 | CureVac AG, Coalition for Epidemic Preparedness Innovations | INDUSTRY | 280 | All | 18 Years ~ 60 Years | Universitair Ziekenhuis Ghent, Ghent, Belgium Ludwig-Maximilians-Universitat Munchen, Munchen, Bavaria, Germany Medical University Hannover (MHH), Hannover, Germany University Hospital Tubingen Institut fur Tropenmedizin, Tubingen, Germany |
| 2302 | Active, not recruiting | A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 | SARS-CoV-2 | Biological: mRNA-1273 Biological: Placebo |
Phase 3 | ModernaTX, Inc., Biomedical Advanced Research and Development Authority | INDUSTRY | 3732 | All | 12 Years ~ 17 Years | Velocity Clinical Research - Banning, Banning, California, United States Paradigm Clinical Research, La Mesa, California, United States Accel Research Sites - Nona Pediatric Center, DeLand, Florida, United States Tekton Research, Chamblee, Georgia, United States Clinical Research Atlanta, Stockbridge, Georgia, United States Velocity Clinical Research - Boise, Meridian, Idaho, United States Velocity Clinical Research - Valparaiso, Valparaiso, Indiana, United States Johnson County Clinical Trials, Lenexa, Kansas, United States Medpharmics - Metairie, Metairie, Louisiana, United States University of Massachusetts Medical School, Worcester, Massachusetts, United States Clinical Research Institute, Minneapolis, Minnesota, United States Medpharmics - Gulfport, Gulfport, Mississippi, United States Medpharmics - Albuquerque, Albuquerque, New Mexico, United States Child Healthcare Associates, Liverpool, New York, United States Velocity Clinical Research - Cincinnati, Cincinnati, Ohio, United States Lynn Health Sciences Institute, Oklahoma City, Oklahoma, United States Velocity Clinical Research - Providence, Warwick, Rhode Island, United States Coastal Pediatric Associates, Charleston, South Carolina, United States Benchmark Research, Austin, Texas, United States Crossroads Clinical Research, Corpus Christi, Texas, United States Kool Kids Pediatrics, Houston, Texas, United States ACRC Trials, Plano, Texas, United States Tekton Research, San Antonio, Texas, United States Tekton Research, San Antonio, Texas, United States Velocity Clinical Research - Salt Lake City - Jordan Valley, West Jordan, Utah, United States |
| 2301 | Completed | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers | Severe Acute Respiratory Syndrome Coronavirus 2 | Drug: Aerolized Hydroxychloroquine Sulfate Other: Placebo |
Phase 1 | Pulmoquine Therapeutics, Inc, Rockefeller University | INDUSTRY | 12 | All | 18 Years | The Rockefeller University, New York, New York, United States |
| 2300 | Active, not recruiting | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study | Covid19 Vaccine | Biological: MVC-COV1901(S protein with adjuvant) | Phase 2 | Medigen Vaccine Biologics Corp. | INDUSTRY | 274 | All | 20 Years | Changhua Christian Hospital, Changhua, Taiwan Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan China Medical University Hospital, Taichung, Taiwan National Cheng Kung University Hospital, Tainan, Taiwan National Taiwan University Hospital, Taipei, Taiwan Taipei Medical University Hospital, Taipei, Taiwan Taipei Municipal Wan Fang Hospital, Taipei, Taiwan Taipei Veteran General Hospital, Taipei, Taiwan Tri-Service General Hospital, Taipei, Taiwan Chang-Guang Memorial Hospital Lin-Kou, Taoyuan, Taiwan Tao-Yuan General Hospital, Taoyuan, Taiwan |
| 2299 | Completed | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine | COVID-19 | Biological: UB-612 | Phase 1 | United Biomedical Inc., Asia, Vaxxinity, Inc. | INDUSTRY | 60 | All | 20 Years ~ 55 Years | China Medical University Hospital, Taichung, Taiwan |
